CJC-1295 with DAC
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC, Modified GRF 1-29 DAC
A long-acting GHRH analog with extended half-life for sustained GH elevation.
Overview
CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone releasing hormone analog with a maleimidopropionic acid group that binds to albumin, dramatically extending its half-life to 6-8 days. This allows for less frequent dosing but creates sustained GH elevation rather than pulsatile release.
Mechanism of Action
Activates GHRH receptors on pituitary somatotrophs to stimulate GH release. The DAC modification binds to serum albumin, protecting from degradation and extending half-life from minutes to days. Creates sustained rather than pulsatile GH elevation.
Pharmacokinetics
Half-life 6-8 days due to albumin binding. Once or twice weekly dosing. Sustained GH and IGF-1 elevation.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard Protocol
1-2 mg
Once or twice weekly
8-12 weeks
Less frequent than non-DAC version
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Dramatically extended half-life vs non-DAC version
- 2Sustained IGF-1 elevation for days
- 3Less frequent dosing required
- 4May cause GH bleed rather than natural pulses
Side Effects & Contraindications
Reported Side Effects
- Water retention
- Tingling
- Fatigue
- Joint pain
Contraindications
- Active malignancy
- Diabetic retinopathy
Safety Considerations
Research compound. Sustained GH elevation differs from natural pulsatile release. May increase side effects vs non-DAC version. Monitor IGF-1 levels.
Storage Requirements
Refrigerate 2-8°C after reconstitution
Scientific References
- 1